1,3,5,7,2,4,6,8-Tetrazatetraphosphocine, 2,2,4,4,6,6,8,8-octahydro-2,6-bis(1-aziridinyl)-2,4,4,6,8,8-hexakis(dimethylamino)-, trans- | 96357-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丙烷
• 英文名称: 1,3,5,7,2,4,6,8-Tetrazatetraphosphocine, 2,2,4,4,6,6,8,8-octahydro-2,6-bis(1-aziridinyl)-2,4,4,6,8,8-hexakis(dimethylamino)-, trans-
• 英文别名: (4S,8R)-4,8-bis(aziridin-1-yl)-2-N,2-N,2-N',2-N',4-N,4-N,6-N,6-N,6-N',6-N',8-N,8-N-dodecamethyl-1,3,5,7-tetraza-2λ5,4λ5,6λ5,8λ5-tetraphosphacycloocta-1,3,5,7-tetraene-2,2,4,6,6,8-hexamine
• CAS: 96357-62-9
• 化学式: C₁₆H₄₄N₁₂P₄
• 分子量: 528.501
• InChiKey: YODDZOLWISPQBI-UEOVJWFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.9
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  二甲胺 、 (2S,6R)-2,6-bis(aziridin-1-yl)-2,4,4,6,8,8-hexachloro-1,3,5,7-tetraza-2lambda5,4lambda5,6lambda5,8lambda5-tetraphosphacycloocta-1,3,5,7-tetraene 以 乙醚 为溶剂， 以68%的产率得到1,3,5,7,2,4,6,8-Tetrazatetraphosphocine, 2,2,4,4,6,6,8,8-octahydro-2,6-bis(1-aziridinyl)-2,4,4,6,8,8-hexakis(dimethylamino)-, trans-
  参考文献：
  名称：

  双（1-氮丙啶基）环磷腈的异构体依赖性细胞抑制活性。

  摘要：

  测试了许多最近合成的无机环系统（NPCl2）3和（NPCl2）4的单和双（1-叠氮基）衍生物的体外（L1210和L5178Y细胞）和体内（腹膜内白血病L1210）的细胞抑制活性。在CDF1小鼠中）。通常，与它们的双取代和单（1-叠氮基）取代的类似物相比，非双基双（1-叠氮基）异构体（反式或顺式）似乎是有效的肿瘤生长抑制剂。提出了生物学活性与烷基化中心数目（即，带有一个或两个叠氮基的P原子）之间的关系。

  DOI：

  10.1021/jm00158a003

文献信息

• Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes
  作者：Adriaan A. Van der Huizen、Theo Wilting、Johan C. Van de Grampel、Peter Lelieveld、Aukje Van der Meer-Kalverkamp、Henk B. Lamberts、Nanno H. Mulder

  DOI：10.1021/jm00158a003

  日期：1986.8

  bis(1-aziridinyl) derivatives of the inorganic ring systems (NPCl2)3 and (NPCl2)4 was tested for their cytostatic activity in vitro (L1210 and L5178Y cells) and in vivo (intraperitoneal leukemia L1210 in CDF1 mice). Generally, the nongeminal bis(1-aziridinyl) isomers (either trans or cis) appear to be potent tumor growth inhibitors in contrast to their geminally substituted and mono(1-aziridinyl)-substituted

  测试了许多最近合成的无机环系统（NPCl2）3和（NPCl2）4的单和双（1-叠氮基）衍生物的体外（L1210和L5178Y细胞）和体内（腹膜内白血病L1210）的细胞抑制活性。在CDF1小鼠中）。通常，与它们的双取代和单（1-叠氮基）取代的类似物相比，非双基双（1-叠氮基）异构体（反式或顺式）似乎是有效的肿瘤生长抑制剂。提出了生物学活性与烷基化中心数目（即，带有一个或两个叠氮基的P原子）之间的关系。
• Silicon-based energy storage devices with phosphazene containing electrolyte additives
  申请人：ENEVATE CORPORATION

  公开号：US11522223B2

  公开（公告）日：2022-12-06

  Electrolytes and electrolyte additives for energy storage devices comprising phosphazene based compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte comprising at least two electrolyte co-solvents, wherein at least one electrolyte co-solvent comprises a phosphazene based compound.

  本发明公开了用于储能装置的电解质和电解质添加剂，其中包含磷苯基化合物。该储能装置包括第一电极和第二电极，其中第一电极和第二电极中的至少一个是硅基电极；第一电极和第二电极之间的隔板；电解液，包括至少两种电解液助溶剂，其中至少一种电解液助溶剂包括磷苯基化合物。
• SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES
  申请人：ENEVATE CORPORATION

  公开号：US20200136185A1

  公开（公告）日：2020-04-30

  Electrolytes and electrolyte additives for energy storage devices comprising phosphazene based compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte comprising at least two electrolyte co-solvents, wherein at least one electrolyte co-solvent comprises a phosphazene based compound.
• Huizen, Adriaan A. van der; Grampel, Johan C. van de; Rusch, Jan W., Journal of the Chemical Society, Dalton Transactions, 1986, p. 1317 - 1328
  作者：Huizen, Adriaan A. van der、Grampel, Johan C. van de、Rusch, Jan W.、Wilting, Theo、Bolhuis, Fre van、Meetsma, Auke

  DOI：——

  日期：——